Windtree Therapeutics Inc (NASDAQ:WINT) — Market Cap & Net Worth
Market Cap & Net Worth: Windtree Therapeutics Inc (WINT)
Windtree Therapeutics Inc (NASDAQ:WINT) has a market capitalization of $793.77K ($793.77K) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30335 globally and #5890 in its home market, demonstrating a 7.27% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Windtree Therapeutics Inc's stock price $0.02 by its total outstanding shares 33634220 (33.63 Million). Analyse WINT cash flow metrics to see how efficiently the company converts income to cash.
Windtree Therapeutics Inc Market Cap History: 2015 to 2026
Windtree Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $5.44 Trillion to $793.77K (-78.32% CAGR).
Index Memberships
Windtree Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #913 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2883 of 3165 |
Weight: Windtree Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Windtree Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Windtree Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1949252.43x
Windtree Therapeutics Inc's market cap is 1949252.43 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $5.44 Trillion | $987.00K | -$55.17 Million | 5510563.52x | N/A |
| 2016 | $2.27 Trillion | $2.04 Million | -$39.49 Million | 1111805.14x | N/A |
| 2017 | $381.41 Billion | $1.49 Million | -$18.45 Million | 256842.67x | N/A |
| 2018 | $454.06 Billion | $1.79 Million | -$20.53 Million | 253949.18x | N/A |
| 2019 | $385.95 Billion | $198.00K | -$27.48 Million | 1949252.43x | N/A |
Competitor Companies of WINT by Market Capitalization
Companies near Windtree Therapeutics Inc in the global market cap rankings as of May 2, 2026.
Key companies related to Windtree Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Windtree Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Windtree Therapeutics Inc's market cap moved from $5.44 Trillion to $ 793.77K, with a yearly change of -78.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $793.77K | -32.38% |
| 2025 | $1.17 Million | -90.01% |
| 2024 | $11.75 Million | -97.30% |
| 2023 | $435.29 Million | -91.54% |
| 2022 | $5.15 Billion | -89.41% |
| 2021 | $48.58 Billion | -68.71% |
| 2020 | $155.29 Billion | -59.76% |
| 2019 | $385.95 Billion | -15.00% |
| 2018 | $454.06 Billion | +19.05% |
| 2017 | $381.41 Billion | -83.20% |
| 2016 | $2.27 Trillion | -58.26% |
| 2015 | $5.44 Trillion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Windtree Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $793.77K USD |
| MoneyControl | $793.77K USD |
| MarketWatch | $793.77K USD |
| marketcap.company | $793.77K USD |
| Reuters | $793.77K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Windtree Therapeutics Inc
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 sur… Read more